

Isolation and Identification of a New Cold and Alkaline Tolerant Antibiotic Producing *Streptomyces* sp. From Soil

Sadaf Sadat Rafati,¹ Bahar Shahnava^{1,2,*} and Ali Makhdoumi¹

¹Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, IR Iran

²Institute of Applied Zoology, Faculty of Sciences, Ferdowsi University of Mashhad, Mashhad, IR Iran

*Corresponding author: Bahar Shahnava, Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, IR Iran. Tel: +98-5138805506, Fax: +98-5138796416, E-mail: shahnava@um.ac.ir

Received 2016 June 18; Revised 2016 October 18; Accepted 2016 October 18.

Abstract

Background: The ever-increasing resistance of microorganisms to pathogens and our inability to control infectious diseases indicate the importance of conducting research to find new antibiotics.

Objectives: The aim of the present research was to isolate, identify, and optimize a cold and pH resistant strain of *Streptomyces* with high antibiotic production capability.

Methods: Soil samples were taken from the Telar forests of northern Iran, and the ACS52 strain was identified as a *Streptomyces* strain based on the morphological, biochemical, and 16S rRNA gene analysis. Antibacterial features of the obtained strain were studied against a wide range of Gram-positive and Gram-negative bacteria using the cross-culture method. In order to evaluate the antibacterial activity of culture product, two seed cultures and three fermentation media were examined. Finally, the effects of various factors such as the type of carbon and nitrogen sources, temperature, pH, and inoculation rate were investigated.

Results: *Streptomyces* sp. ACS52 is a cold-resistant alkalophilic bacterium strain with antibacterial activity against a broad spectrum of pathogenic bacteria. The fermentation medium containing glycerol and ethyl acetate was suitable for the production and extraction of antibacterial compound, respectively. Glycerol and starch as the carbon source, soybean extract as the nitrogen source, temperature of 25°C, pH of 7, and inoculation rate of 10% were found to provide the optimal conditions for the antibacterial activity.

Conclusions: The crude extract of *Streptomyces* sp. ACS52 had high antibacterial activity against a wide spectrum of bacteria and could be of interest due to its features such as ability to grow at low temperatures and alkaline pH levels.

Keywords: *Streptomyces* sp., Telar Forests, Optimization

1. Background

Because of the ever-increasing resistance of pathogenic microorganisms, sensitivity of patients to some antibiotics, and inability of controlling infectious diseases, the research to find new antimicrobial compounds in biological sources has kept its importance up to the present time (1). Various antibiotics have been found in numerous microorganisms from different habitats. Soil bacteria and fungi play an important role in the production of antibiotics (2, 3). Structure and diversity of these microorganisms depend on various factors such as the available nutrient resources, soil texture, plants cover, and soil pH (4). *Actinomycetes* are Gram-positive, usually filamentous, immobile, and often obligate aerobes with aerial mycelia whose DNA base composition includes 67% - 78% G + C (5). These bacteria are very important in biotechnology industries due to their ability to produce secondary metabolites.

About 75% of all the known commercially and medically useful antibiotics are obtained from *Streptomyces* (6, 7). *Streptomyces* are one of the most important groups of *Actinomycetes* that can survive under a broad range of harsh conditions in soil and they are a crucial source for

a wide range of biologically active compounds (6). It is estimated that *Streptomyces* species have a potential to produce over 150,000 different bioactive compounds (8). These metabolites not only include antibiotics, but also engage extracellular enzymes, antiviral herbicides, antitumor, and anticancer drugs.

These metabolites may be the most various, particular, and complicated substances with excellent properties and usually low toxicity (6). It seems that large genome of these bacteria allows them to respond to specific needs and therefore produce diverse metabolites (9). The production of antimicrobial compound in *Streptomyces* spp. is greatly influenced by various fermentation parameters such as available nutrients (10), pH, temperature (11), mineral salts (12), precursors (13), and inducers (14). These parameters can be varied from organism to organism (15).

2. Objectives

The aim of this study was to isolate and identify a strain of *Streptomyces* from unexplored environments and evaluate its antimicrobial products.

3. Methods

3.1. Materials

Various inorganic salts (CaCO₃, FeSO₄, K₂HPO₄, MgSO₄, NaCl, KNO₃, CoCl₂, NH₄NO₃, and NaNO₃), Mueller-Hinton agar, starch, glycerol, peptone, malt extract, dextrin, meat extract, yeast extract, tryptone, and soy meal were purchased from Merck (Darmstadt, Germany). Liquid solvents (ethyl acetate, dichloromethane, and chloroform) were prepared from Dr. Mojallali Chemical Lab. DNA Extraction Kit was purchased from FastDNA® SPIN Kit (Qbiogene, Canada). The PCR reagents were purchased from CinnaGen (CinnaGen Co. Iran). The F/R primers were purchased from DenaZiat (Mashhad, Iran). All other chemicals used were of analytical grade.

3.2. Soil Sampling

Soil samples were taken under sterile conditions from the depth of 10 cm in the Telar forests (Iran north, 52°53' E, 36°28' N). Ten grams of the soil sample were put in 90 mL of physiological serum, centrifuged at 150 rpm for 30 minutes, and placed in a warm water bath at 65°C for 15 minutes (16). Starch Casein Agar (per 1.0 L: 10 g starch, 0.02 g CaCO₃, 0.01 g FeSO₄, 2 g K₂HPO₄, and 15 g agar) (17) and Glycerol Casein Agar (per 1.0 L: 10 g glycerol, 0.3 g casein, 2 g K₂HPO₄, 0.01 g FeSO₄, 0.05 g MgSO₄, 0.02 g CaCO₃, 2 g NaCl, and 2 g KNO₃, and 15 g agar) (2) culture media were used to isolate *Actinomycetes*. To prevent fungal growth, the antibiotic cycloheximide at 100 µg/mL was used. The culture media were incubated at 25 - 30°C for 2 - 4 weeks, and then analyzed for the presence of *Actinomycete* colonies.

3.3. Biochemical and Molecular Characterization

Morphological, physiological, and biochemical characteristics of the ACS52 strain such as growth at various temperatures and pH, presence of hydrolytic enzymes including amylase, gelatinase, protease, cellulase, urease, citratase, and tyrosinase, and fermentation of some sugars were studied (18). Extraction of genomic DNA was performed using FastDNA® SPIN Kit from fresh and purified culture medium according to the manufacturer's instructions. The 16S rRNA gene was amplified using primers 27F and 1492R. PCRs were carried out with 1.5 mM MgCl₂, 10X buffer, 0.2 mM dNTP, 0.5 mM of each primer, and 0.6 unit of Taq polymerase under the conditions as follows: initial denaturation at 95°C for 120 s, 35 cycles of denaturation at 95°C for 30 seconds, annealing at 49°C for 30 seconds, and the extension at 72°C for 90 seconds and 30 seconds.

The PCR products were purified and sequenced at Macrogen, South Korea. The obtained sequences were compared with NCBI and Ez-Taxon. The 16S rRNA sequences of

ACS52 were aligned with the published sequences of related species using the Clustal W software, and were analyzed using the Maximum Likelihood pattern in the MEGA software 6.0. Bootstrap analysis was used to evaluate the tree topology by performing 1000 resamplings.

3.4. Preliminary Screening

The ACS52 strain was cultured in the centers of the Mueller-Hinton agar plates and incubated at 25°C for 96 hours. The Gram-positive pathogens including *Staphylococcus aureus* PTCC1431 (U), *S. epidermidis* PTCC1435, *S. saprophyticus* PTCC1440, *S. intermedius*, *S. chromogenes*, Methicillin resistant *S. aureus*, *S. aureus* (D), *Listeria monocytogenes* PTCC1298, *Bacillus subtilis* PTCC1365 and Gram-negative pathogens including *Salmonella typhimurium* ATCC14028, *Pseudomonas aeruginosa* PTCC1074, *Escherichia coli* (R) PTCC1399, *E. coli* O157: H7 NCTC 12900, *E. coli* (H), *E. coli* (I), *Acinetobacter* (F), *Acinetobacter* (G), and *Klebsiella* were used as test bacteria. A standard concentration of the test bacteria was streaked perpendicular to the antagonist on the agar medium. The plates were incubated at 37°C for 18 - 24 hours (19), and the growth inhibition zones were measured in mm.

3.5. Selection of the Seeding and Fermentation Media for Antibiotic Production

Two media for seed culture and three media for fermentation were studied to select the best fermentation media for antibiotic production. The seed culture media included Medium A (per 1.0 L: Malt extract 10 g, Yeast extract 4 g, Glucose 4 g) (20) and Medium B (per 1.0 L: Peptone 10 g, Malt extract 10 g, Glycerol 10 g) (20), while the fermentation media were Hickey-Tresner Medium (per 1.0 L: Dextrin 10 g, Meat extract 1 g, Yeast extract 1 g, Tryptone 2 g, CoCl₂ 0.02 g) (18), Glycerol Soy Meal (per 1.0 L: Glycerol 15 g, Soy meal 10 g, NaCl 5 g, CaCO₃ 1 g, CoCl₂ · 7H₂O 0.001 g) (21), and Glycerol Medium (per 1.0 L: Glycerol 30 g, Casein peptone 2 g, NaCl 1 g, K₂HPO₄ 1 g, MgSO₄ · 7H₂O 0.5 g) (21). The pH of media was adjusted at seven.

Two milliliter of the spore suspension was inoculated to 80 ml of the seed medium and incubated at 30°C for 42 - 48 hours at the speed of 200 rpm. The culture media were then examined for the absence of spores and contamination, and presence of growing hyphae. Then, 2 mL of the seed culture was inoculated to 40 ml of the fermentation medium, and incubated at 30°C for 7 days at the speed of 200 rpm. The fermentation broth was centrifuged at 10000 rpm for 20 minutes and filtered (0.22 µm). 100 µL of standard concentrations from bacterial pathogens were spread on the Muller-Hinton agar medium. Using sterile

stainless steel cylinders, wells were formed in the Muller-Hinton agar. 100 μL of the fermentation broth was transferred to the wells and incubated at 37°C for 24 hours and inhibition zones were measured (22).

3.6. Extraction of Antibacterial Activity

The antimicrobial compound was extracted from the fermentation medium by three liquid solvents including ethyl acetate, dichloromethane, and chloroform. The fermentation broth was centrifuged at 4000 rpm for 20 minutes at 4°C. The supernatant was separated and divided into three equal volumes. The each portion mixed with equal volume of solvent-liquid and the mixture (media and solvent) was shaken for 1 hour and kept stationary for 15 minutes to separate the organic phase from the aqueous phase. The organic phase that contained the antimicrobial compound was concentrated in rotary vacuum evaporator at 35°C in low pressure and kept at 4°C (23).

3.7. In Vitro Antibacterial Assay

The antibacterial activity of the solvent extract of ACS52 was determined by the disc diffusion method against the pathogens bacteria (24). 100 μL of overnight culture of the pathogen was spread on the Muller-Hinton agar medium. 250 μL of each organic fraction was added gradually to paper discs (Padtan Teb Co. Iran). The paper disk was transferred to the Muller-Hinton agar culture. Each organic solvent was added to paper disc with an equal load of pathogen cell and used as control. The culture media were incubated at 35°C for 18 - 24 hours, and diameter of inhibition zone was measured.

3.8. Optimization of the Fermentation Medium

For optimization, all variables were kept constant on a contract basis at any stage of optimization, and only the effect of one variable was studied to determine its optimal level. In the next step, the optimized variable in the previous step was used as a basis.

The different carbon sources (glucose, dextrose, starch, and glycerol) were investigated by adding each at the concentration of 1% w/v. To determine the optimum concentration of the best carbon source, 0.5, 1, 1.5, 2, 2.5, and 3% concentrations (w/v) were added (25). Then, the effects of various nitrogen sources (peptone, tryptone, yeast extract, ammonium nitrate, sodium nitrate, soybean extract, and malt extract, 0.2% w/v) were also investigated. Next, the different concentrations of the most effective nitrogen source were used at 0.2, 0.4, 0.6, 0.8, 1, 1.2, and 1.6% w/v (25). The different conditions of culture at various pH levels (4, 6.5, 7, 8, and 9), temperatures (15, 20, 25, 30, and 37°C) (26), inoculation rates of the seed culture medium to the fermentation

medium (2.5, 5, 7.5, 10, 12.5, and 15%), and incubation time (4, 5, 6, 7, 8, 9 and 10 days) were also studied. The fermentation culture was centrifuged at 4000 rpm for 20 minutes at 4°C (27).

3.9. Statistical Analysis

All experiments were replicated three times. One-way analysis of variance (ANOVA) at the 95% confidence level was performed using R software (28).


4. Results

The *Streptomyces* sp. strain ACS52 that was obtained from soil samples in the Telar forests of northern Iran was 99.8% similar to *Streptomyces* spiroverticillatus. The GenBank accession of sequence was KT232070. Table 1 presents the physiological and biochemical characteristics of *Streptomyces* sp. strain ACS52. This strain was able to hydrolyze starch and cellulose but not able to hydrolyze casein, urea, gelatin, or citrate. ACS52 was a facultative psychrophilic and alkalophilic *Streptomyces* sp. strain. The phylogenetic tree obtained by the maximum likelihood algorithm is shown in Figure 1.

Primary screening of ACS52 for its antibacterial activity revealed that it had antibiotic activity against a broad spectrum of pathogenic bacteria as well as some antibiotic resistant bacteria found at a city hospital (Table 2). Average diameter of growth inhibition zone against Gram-positive and Gram-negative bacteria was 25 ± 0.06 and 22.5 ± 0.11 mm, respectively. *S. epidermidis* PTCC1435 and Methicillin resistant *S. aureus* among the Gram-positive bacteria, and *E. coli* (H) and *Klebsiella* among the Gram-negative bacteria showed the most sensitivity in the primary screening. Results indicated there were no significant differences between the various seed culture used to produce antibacterial compounds ($P = 0.21$), but the fermentation media were drastically different in the amount of the produced antibacterial compounds. The glycerol soy meal culture was particularly different from the other media ($P < 0.0001$).

Table 3 presents diameters of inhibition zones of the fermentation broth fraction extracts by the various organic solvents. Results showed that ethyl acetate was the best solvent for antibiotic extraction compared to the other solvents. Various factors were evaluated using one factor at a time to optimize the conditions for the production of antibacterial compound by ACS52 strain. The optimization results revealed that *Streptomyces* sp. strain ACS52 could grow in all of the studied culture media, but these media had different effects on the inhibition zones. Statistical analysis showed that complex carbon

Figure 1. 16S rRNA Tree Showing the Phylogenetic Relationship Between Obtained Strain and Other Known *Streptomyces* Species



Clustering was performed using the maximum likelihood method with 1000 bootstraps. *Microbacterium esteraromaticum* was chosen as out-group.

Table 1. Biochemical Characteristics of *Streptomyces* sp. strain ACS52 Isolated From Soil Samples of Telar Forest, North of Iran

Biochemical Characteristics		Sugar Fermentation		Growth Temperature (°C)		Growth pH	
Catalase test	+	Glucose	+	4	+	5	-
Gelatin hydrolysis	-	Lactose	+	20	+	7	+
Starch hydrolysis	-	Sucrose	+	25	+	9	+
Cellulose hydrolysis	+			30	+		
Casein hydrolysis	-			37	+		
Tryptophan hydrolysis	-			55	-		
Urease test	-						
Melanin production	-						
H ₂ S production	+						

Table 2. Inhabitation Zone of *Streptomyces* sp. Strain ACS52 Against the Pathogenic Bacteria Using Cross-Streak Method^{a,b}

Gram Positive	Zone Inhibition	Gram Negative	Zone Inhibition
<i>Staphylococcus aureus</i> PTCC1431 (U)	25 ± 0.05	<i>Salmonella typhimurium</i> ATCC14028	23 ± 0.15
<i>S. aureus</i> (D)	23 ± 0.05	<i>Escherichia coli</i> (R) PTCC1399	23 ± 0.11
Methicillin resistant <i>S. aureus</i>	28 ± 0.11	<i>E. coli</i> O157: H7 NCTC12900	21 ± 0.15
<i>S. intermedius</i>	24 ± 0.05	<i>E. coli</i> (H)	27 ± 0.11
<i>S. chromogenes</i>	22 ± 0	<i>E. coli</i> (I)	19 ± 0
<i>S. saprophyticus</i> PTCC1440	27 ± 0	<i>Acinetobacter</i> (F)	21 ± 0.17
<i>S. epidermidis</i> PTCC1435	3 ± 0	<i>Acinetobacter</i> (G)	21 ± 0.1
<i>Listeria monocytogenes</i> PTCC1298	23 ± 0.15	<i>Pseudomonas aeruginosa</i> PTCC1074	22 ± 0.2
<i>Bacillus subtilis</i> PTCC1365	19 ± 0.17	<i>Klebsiella</i> (ESBLs)	25 ± 0

^aThe bacteria with standard reference were obtained from a microbiology laboratory at Ferdowsi University of Mashhad, and other bacteria were collected from antibiotic resistant strains at Ghaem hospital in Mashhad.

^bValues are expressed as mean ± SD.

sources such as glycerol and starch were more effective than monomer ones. Raising the concentration of the glycerol from 0.5 to 2% increased the production of the antibacterial compound; however, the production rate decreased when the concentration exceeded 2%. Among the different nitrogen sources examined, yeast extract, tryptone, and sodium nitrate prevented the production of the antibacterial compound, while the maximum production was observed in the presence of soybean extract and peptone (Figure 2).


Moreover, the highest inhibition zone was observed for the culture at pH 7.0. *Streptomyces* sp. strain ACS52 grew in a wide range of temperature, but the highest inhabitation zone was observed when it was cultivated at 25°C while the zone declined at 30°C and 37°C. Finally, 10% v/v inoculation rate led to the maximum antibacterial production (Figure 3).

5. Discussion

Because of the indiscriminate use of drugs, drug resistance has turned into one of the biggest problems of human societies. This confusion has led to the study of the ability of microorganisms to control diseases and evaluate their secondary products in order to find new pharmaceutical and medical compounds (24). *Actinomycetes*, especially *Streptomyces*, are one of the major bacterial groups in biotechnological industries due to their ability to produce various types of secondary metabolites (29, 30). In the present study, *Streptomyces* sp. ACS52, with a broad range of antibacterial activities, was selected for optimization of its antibacterial properties. The ACS52 isolate grew at both 4°C and 37°C, and therefore was considered as a cold tolerant bacterium. The antibacterial activity of *Actinomycetes* may stem from the fact that they produce numerous enzymes that can affect various structures of pathogens and

Table 3. Diameter of Inhibition Zones of Different Fermentation Medium Extracts (mm)

Aqueous Phase	<i>S. chromogenes</i>	<i>S. chromogenes</i>	MRSA	<i>S. aureus</i> (U)	<i>B. subtilis</i>	<i>E. coli</i> (H)	<i>E. coli</i> (I)	<i>E. coli</i> O157: H7	<i>E. coli</i> (R)	<i>S. typhimurium</i>	<i>P. aeruginosa</i>
Ethyl acetate	18	18	20	20	15	12	15	18	14	15	18
Dichloromethane	12	17	18	15	12	11	15	13	12	15	15
Chloroform	12	12	18	12	12	0	13	0	0	7	11

Figure 2. Effect of Carbon Source (A), Glycerol Percentage (B), Nitrogen Source (C), and Soy Extract Percentage (D) on the Antibacterial Compound Production by *Streptomyces* sp. Strain ACS52

Cultivation was performed at 30°C and pH 7. Vertical bars represent standard deviation (n = 3).


control their growth. The production of these enzymes under extreme conditions, in comparison with normal conditions, gives unique features to the enzymes, and may lead their effectiveness to be improved against pathogens. The cold tolerant bacteria can be suitable candidates for research to find new antibacterial compounds (31).

The present study showed the *Streptomyces* sp. strain ACS52 had the capability to produce an antibacterial compound against all of the studied Gram-positive and Gram-negative pathogens, although the average diameter of inhibition zone was higher for Gram-positive bacteria. The fermentation culture could show significant effects in the antibacterial activity (23).

Numerous solvents were used in this study to extract the antibacterial compounds. Ethyl acetate extract (as a non-polar solvent) had maximum antibacterial activity compared to dichloromethane and chloroform extracts (as polar solvents). Therefore, the antibacterial compound produced by *Streptomyces* sp. strain ACS52 probably has

non-polar structure. The results of the optimization of culture conditions indicated that the highest antibacterial production was observed at culture pH of 7, inoculation rate of 10%, and incubation time of 7 days (168 hours) at 25°C. These results are quite comparable with those reported in other studies (27, 32, 33). The results obtained under the optimal culture conditions showed that the antibacterial compound production was lowest in the presence of glucose (especially against Gram-negative bacteria). However some of researches showed that the addition of glucose to the culture medium increased the production of antibiotic activity (34). In this regard, a research carried out by Abdelwahed (27) indicated starch directly related to the increased inhibition zones.

The present study showed that *Streptomyces* sp. strain ACS52 has a broad spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. It also revealed that the optimization of culture conditions is effective in increasing the production of antibacterial com-

Figure 3. Effect of pH (A), Temperature (B), Inoculation Rate (C), and Incubation Time (D) on the Antibacterial Compound Production by *Streptomyces* sp. Strain ACS52

Vertical bars represent standard deviation (n = 3).

pound. Further investigation on the purification and characterization of antibacterial compound produced by this strain would lead to some products useful in pharmaceutical applications.

Acknowledgments

We are very grateful to the laboratory of microbiology and biotechnology, department of biology, faculty of science. We are also immensely grateful to Dr. Kiarash Ghazvini from Ghaem hospital.

Footnotes

Authors' Contribution: Bahar Shahnava and Ali Makhdomi developed the original idea and protocol and contributed to the preparation of the manuscript; Sadaf-Sadat Rafati conducted the antibacterial tests and identified *Streptomyces* sp.

Funding/Support: This study was supported by Ferdowsi University of Mashhad with grant no. 31039/3.

References

- Prabavathy VR, Mathivanan N, Murugesan K. Control of blast and sheath blight diseases of using antifungal metabolites produced by *Streptomyces* sp. PM5. *Biol Control*. 2006;**39**(3):313-9. doi: [10.1016/j.biocontrol.2006.07.011](https://doi.org/10.1016/j.biocontrol.2006.07.011).
- El-Nakeeb MA, Lechevalier HA. Selective isolation of aerobic Actinomycetes. *Appl Microbiol*. 1963;**11**:75-7. [PubMed: [13937509](https://pubmed.ncbi.nlm.nih.gov/13937509/)].
- Saadoun I, Gharaibeh R. The *Streptomyces* flora of Jordan and its potential as a source of antibiotics active against antibiotic-resistant Gram-negative bacteria. *World J Microbiol Biotechnol*. 2002;**18**(5):465-70. doi: [10.1023/A:1015531205871](https://doi.org/10.1023/A:1015531205871).
- Seviour RJ, Kragelund C, Kong Y, Eales K, Nielsen JL, Nielsen PH. Ecophysiology of the Actinobacteria in activated sludge systems. *Antonie Van Leeuwenhoek*. 2008;**94**(1):21-33. doi: [10.1007/s10482-008-9226-2](https://doi.org/10.1007/s10482-008-9226-2). [PubMed: [18299961](https://pubmed.ncbi.nlm.nih.gov/18299961/)].
- Meena B, Rajan LA, Vinithkumar NV, Kirubakaran R. Novel marine actinobacteria from emerald Andaman & Nicobar Islands: a prospective source for industrial and pharmaceutical byproducts. *BMC Microbiol*. 2013;**13**(1):1. doi: [10.1186/1471-2180-13-145](https://doi.org/10.1186/1471-2180-13-145).
- Berdy J. Bioactive microbial metabolites. *J Antibiot (Tokyo)*. 2005;**58**(1):1-26. doi: [10.1038/ja.2005.1](https://doi.org/10.1038/ja.2005.1). [PubMed: [15813176](https://pubmed.ncbi.nlm.nih.gov/15813176/)].
- Kieser T. Practical streptomyces genetics. John Innes Foundation; 2000.
- Watve MG, Tickoo R, Jog MM, Bhole BD. How many antibiotics are produced by the genus *Streptomyces*?. *Arch Microbiol*. 2001;**176**(5):386-90. doi: [10.1007/s002030100345](https://doi.org/10.1007/s002030100345). [PubMed: [11702082](https://pubmed.ncbi.nlm.nih.gov/11702082/)].
- Gargasas LI, Zhizhene TA, Kalashaitite LI, Kuizinen PA, Meshkauskene Ia I. [Accuracy and variability of medical interpretation of the electrocardiogram]. *Kardiologija*. 1976;**16**(2):107-11. doi: [10.1128/JB.184.12.3411-3415.2002](https://doi.org/10.1128/JB.184.12.3411-3415.2002). [PubMed: [135112](https://pubmed.ncbi.nlm.nih.gov/135112/)].
- Fourati-Ben Fguira L, Fotso S, Ben Ameer-Mehdi R, Mellouli L, Laatsch H. Purification and structure elucidation of antifungal and antibacterial activities of newly isolated *Streptomyces* sp. strain US80. *Res Microbiol*. 2005;**156**(3):341-7. doi: [10.1016/j.resmic.2004.10.006](https://doi.org/10.1016/j.resmic.2004.10.006). [PubMed: [15808937](https://pubmed.ncbi.nlm.nih.gov/15808937/)].
- Sujatha P, Bapi Raju KV, Ramana T. Studies on a new marine streptomycete BT-408 producing polyketide antibiotic SBR-22 effective against methicillin resistant *Staphylococcus aureus*. *Microbiol Res*. 2005;**160**(2):119-26. doi: [10.1016/j.micres.2004.10.006](https://doi.org/10.1016/j.micres.2004.10.006). [PubMed: [15881828](https://pubmed.ncbi.nlm.nih.gov/15881828/)].

12. Wang YH, Yang B, Ren J, Dong ML, Liang D, Xu AL. Optimization of medium composition for the production of clavulanic acid by *Streptomyces clavuligerus*. *Process Biochem.* 2005;**40**(3):1161-6. doi: [10.1016/j.procbio.2004.04.010](https://doi.org/10.1016/j.procbio.2004.04.010).
13. Louis SL, Brivio-Haugland RP, Williams MA. Effect of essential fatty acid deficiency on activity of liver plasma membrane enzymes in the rat. *J Supramol Struct.* 1976;**4**(4):487-96. doi: [10.1002/jss.400040408](https://doi.org/10.1002/jss.400040408). [PubMed: [180355](https://pubmed.ncbi.nlm.nih.gov/180355/)].
14. Cheng YR, Fang A, Demain AL. Effect of amino acids on rapamycin biosynthesis by *Streptomyces hygroscopicus*. *Appl Microbiol Biotechnol.* 1995;**43**(6):1096-8. doi: [10.1007/BF00166931](https://doi.org/10.1007/BF00166931). [PubMed: [8590661](https://pubmed.ncbi.nlm.nih.gov/8590661/)].
15. Stanbury P, Whitaker A, Hall S. Effluent treatment. Principles of fermentation technology. 2 ed. India: Aditya Books; 1997. pp. 313-29.
16. Takizawa M, Colwell RR, Hill RT. Isolation and diversity of actinomycetes in the Chesapeake bay. *Appl Environ Microbiol.* 1993;**59**(4):997-1002. [PubMed: [16348922](https://pubmed.ncbi.nlm.nih.gov/16348922/)].
17. Kuester E, Williams ST. Selection of Media for Isolation of Streptomycetes. *Nature.* 1964;**202**:928-9. [PubMed: [14190108](https://pubmed.ncbi.nlm.nih.gov/14190108/)].
18. Shirling ET, Gottlieb D. Methods for characterization of Streptomyces species. *Int J Syst Evol Microbiol.* 1966;**15**(3):313-40. doi: [10.1099/00207713-16-3-313](https://doi.org/10.1099/00207713-16-3-313).
19. McCabe JJ. What to do if you are sued for malpractice. *J Leg Med (NY).* 1974;**2**(3):21-5. [PubMed: [4546244](https://pubmed.ncbi.nlm.nih.gov/4546244/)].
20. Wink J. The Actinomycetales: an order in the class Actinobacteria important to the pharmaceutical industry-Electronic manual. Aventis Pharma Deutschland GmbH; 2002.
21. Guillemainault C, Flagg WH, Coburn SC, Dement WC. Baclofen trial in six myotonic dystrophy patients. *Acta Neurol Scand.* 1978;**57**(3):232-8. [PubMed: [352086](https://pubmed.ncbi.nlm.nih.gov/352086/)].
22. Hamed J, Mohammadpanah F, Amoozegar M, Dehghan S. Isolation of a new moderately halophilic broad-spectrum antibiotic producing actinobacter. *Jundishapur J Nat Pharm Products.* 2007;**2**(2):94-104.
23. Kumar V, Bharti A, Gupta VK, Gusain O, Bisht GS. Actinomycetes from solitary wasp mud nest and swallow bird mud nest: isolation and screening for their antibacterial activity. *World J Microbiol Biotechnol.* 2012;**28**(3):871-80. doi: [10.1007/s11274-011-0884-2](https://doi.org/10.1007/s11274-011-0884-2). [PubMed: [22805807](https://pubmed.ncbi.nlm.nih.gov/22805807/)].
24. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. *Science.* 1994;**264**(5157):375-82. doi: [10.1126/science.8153624](https://doi.org/10.1126/science.8153624). [PubMed: [8153624](https://pubmed.ncbi.nlm.nih.gov/8153624/)].
25. Usha Kiranmayi M, Sudhakar P, Sreenivasulu K, Vijayalakshmi M. Optimization of Culturing Conditions for Improved Production of Bioactive Metabolites by *Pseudonocardia* sp. VUK-10. *Mycobiology.* 2011;**39**(3):174-81. doi: [10.5941/MYCO.2011.39.3.174](https://doi.org/10.5941/MYCO.2011.39.3.174). [PubMed: [22783100](https://pubmed.ncbi.nlm.nih.gov/22783100/)].
26. Kiranmayi MU, Sudhakar P, Sreenivasulu K, Vijayalakshmi M. Optimization of culturing conditions for improved production of bioactive metabolites by *Pseudonocardia* sp. VUK-10. *Mycobiol.* 2011;**39**(3):174. doi: [10.5941/MYCO.2011.39.3.174](https://doi.org/10.5941/MYCO.2011.39.3.174). [PubMed: [22783100](https://pubmed.ncbi.nlm.nih.gov/22783100/)].
27. Nayera AM, Abdelwahed Nagwa A, Abdallah Dina E, El-Ghawas Said M, Badr EL-Din Ahmed I, El-Diwany . Isolation, identification and optimization of antimicrobial metabolites produced by soil derived actinomycetes. *Egypt J Exp Biol.* 2012;**8**(2):205-17.
28. The R development Core Team . A language and Environment for Statistical Computing. R Foundation for Statistical Computing. Wien; 2007.
29. Jeffrey L. Isolation, characterization and identification of actinomycetes from agriculture soils at Semongok, Sarawak. *Afr J Biotechnol.* 2008;**7**(20) doi: [10.4314/ajb.v7i20.59415](https://doi.org/10.4314/ajb.v7i20.59415).
30. Boudjella H, Bouti K, Zitouni A, Mathieu F, Lebrihi A, Sabaou N. Taxonomy and chemical characterization of antibiotics of Streptoporangium Sg 10 isolated from a Saharan soil. *Microbiol Res.* 2006;**161**(4):288-98. doi: [10.1016/j.micres.2005.10.004](https://doi.org/10.1016/j.micres.2005.10.004). [PubMed: [16338126](https://pubmed.ncbi.nlm.nih.gov/16338126/)].
31. Lo Giudice A, Bruni V, Michaud L. Characterization of Antarctic psychrotrophic bacteria with antibacterial activities against terrestrial microorganisms. *J Basic Microbiol.* 2007;**47**(6):496-505. doi: [10.1002/jobm.200700227](https://doi.org/10.1002/jobm.200700227). [PubMed: [18072250](https://pubmed.ncbi.nlm.nih.gov/18072250/)].
32. Narayana K, Vijayalakshmi M. Optimization of antimicrobial metabolites production by *Streptomyces albidoflavus*. *Res J Pharmacol.* 2008;**2**(1):4-7.
33. Arasu MV, Rejiniemon TS, Al-Dhabi NA, Duraipandian V, Ignacimuthu S, Agastian PKS. Nutritional requirements for the production of antimicrobial metabolites from *Streptomyces*. *Afr J Microbiol Res.* 2014;**8**(8):750-8. doi: [10.5897/AJMR2013.6351](https://doi.org/10.5897/AJMR2013.6351).
34. Khandan Dezfully N, Gottravalli Ramanayaka J. Isolation, Identification and Evaluation of Antimicrobial Activity of *Streptomyces flavogriseus*, strain ACTK2 from Soil Sample of Kodagu, Karnataka State (India). *Jundishapur J Microbiol.* 2015;**8**(2):15107. doi: [10.5812/jjm.15107](https://doi.org/10.5812/jjm.15107). [PubMed: [25825640](https://pubmed.ncbi.nlm.nih.gov/25825640/)].